Until date, therapeutic decisions are heavily dependent on the histological subtype of lung cancer (SQC vs. non-SQC) and its molecular characteristics (e.g., EGFR mutation and ALK rearrangement states). The gene discussed is EGFR; the disease is lung carcinoma.